| abstract |
A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of natalizumab antibody, among others, polysorbate 80, a buffer that inhibits the oxidation of polysorbate containing sodium chloride and phosphates, among others, is described together with the methods for preparing . Also described are formulations with high concentrations of antibodies which maintain fixed volumes and can be used in patients of variable weight. |